UniProtKB/SwissProt variant VAR

Variant information

Variant position:

531

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

LP/P [Disclaimer]

The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Arginine (R) to Glycine (G) at position 531 (R531G, p.Arg531Gly).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Change from large size and basic (R) to glycine (G)

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

-2

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Variant description:

In WPWS; absence of cardiac hypertrophy; onset in childhood; impaired AMP- and ATP-binding.

Any additional useful information about the variant.

Other resources:

Links to websites of interest for the variant.

Variant rs121908990 [ dbSNP | Ensembl ]

Sequence information

Variant position:

531

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

569

The length of the canonical sequence.

Location on the sequence:

CNKLEILETIVDRIVRAEVH R LVVVNEADSIVGIISLSDIL

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         CNKLEILETIVDRIVRAEVHRLVVVNEADSIVGIISLSDIL

Mouse                         CSKLETLETIVDRIVRAEVHRLVVVNEADSIVGIISLSDIL

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 569	5'-AMP-activated protein kinase subunit gamma-2
Domain	504 – 562	CBS 4
Nucleotide binding	530 – 531	ADP 2
Nucleotide binding	530 – 531	AMP 2
Nucleotide binding	530 – 531	ATP 2
Binding site	530 – 530	AMP 3

Literature citations

CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations.
Scott J.W.; Hawley S.A.; Green K.A.; Anis M.; Stewart G.; Scullion G.A.; Norman D.G.; Hardie D.G.;
J. Clin. Invest. 113:274-284(2004)
Cited for: DOMAIN CBS; AMP-BINDING; ATP-BINDING; CHARACTERIZATION OF VARIANTS WPWS GLN-302; ARG-383 AND ASN-400; CHARACTERIZATION OF VARIANT WPWS GLY-531; FUNCTION;

Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy.
Gollob M.H.; Seger J.J.; Gollob T.N.; Tapscott T.; Gonzales O.; Bachinski L.; Roberts R.;
Circulation 104:3030-3033(2001)
Cited for: VARIANT WPWS GLY-531;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9UGJ0: Variant p.Arg531Gly